BAY80-6946

DRUG2 trials

Sponsors

Bayer

Conditions

Neoplasms

Phase 1

Japanese BAY80-6946 Monotherapy Phase I Study

CompletedNCT01404390

Start: 2011-08-18End: 2012-07-12Updated: 2017-12-14

Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer

CompletedNCT01460537

Start: 2011-11-18End: 2015-12-18Updated: 2017-10-04

Related Papers

A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors.

2016-12-0336 citations

Phase 1 dose escalation study of copanlisib (BAY 80-6946) in combination with gemcitabine or gemcitabine-cisplatin in advanced cancer patients.

Journal of Clinical Oncology2014-05-206 citations